SCHEMBL20533951

SCHEMBL20533951

CCOC(=O)N1CCN(c2cc(NC(=O)OC(C)(C)C)n3nc(C)c(Br)c3n2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.40
MAPT P10636 4/20 0.40
ALDH1A1 P00352 4/20 0.40
GAA P10253 4/20 0.40
KDM4E B2RXH2 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HSD17B10 Q99714 2/20 0.40
TP53 P04637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CASP1 P29466 1/20 0.40
ATM Q13315 1/20 0.40
HTT P42858 1/20 0.38
CKS1B P61024 2/20 0.38
SKP1 P63208 2/20 0.38
SKP2 Q13309 2/20 0.38
DPP4 P27487 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
RAD52 P43351 1/20 0.38
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14413660 0.78 CKS1B (0.45) MAPTSMN1; SMN2CKS1BSKP1SKP2
SCHEMBL20533575 0.76 SMN1; SMN2 (0.42) ALDH1A1GAAKDM4ESMN1; SMN2HSD17B10
SCHEMBL14413677 0.75 CKS1B (0.48) MAPTSMN1; SMN2CKS1BSKP1SKP2
SCHEMBL22686415 0.72 GPR4 (0.52) MAPTALDH1A1CKS1BSKP1SKP2
SCHEMBL17690946 0.72 CKS1B (0.49) MAPTSMN1; SMN2CKS1BSKP1SKP2
SCHEMBL20533930 0.71 SMN1; SMN2 (0.39) ALDH1A1KDM4ESMN1; SMN2HSD17B10HTT
SCHEMBL14050908 0.69 TYK2 (0.39) CKS1BSKP1SKP2
SCHEMBL14413674 0.69 CKS1B (0.51) CKS1BSKP1SKP2
SCHEMBL30899646 0.66 CKS1B (0.60) HPGDMAPTALDH1A1SMN1; SMN2CKS1B
SCHEMBL31275758 0.66 BRD9 (0.39) HPGDMAPTALDH1A1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180298009-A1 Fused Pyrazole Derivatives As Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2018-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180298009-A1 Fused Pyrazole Derivatives As Kinase Inhibitors PI4KA, PI4K2B, PI4KB HPGD 3977/4885MAPT 2367/4885ALDH1A1 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.